KRAS is a GTPase that switches from an active GTP-bound conformation and an inactive GDP-bound conformation. Recently, several covalent KRAS G12C inhibitors that stick the protein in its GDP-bound inactive state have reached the clinic. However, the clinical benefit to date is limited and there is a need for next-generation compounds with better target engagement.
Full-Life Technologies Ltd. has received IND clearance by the FDA, allowing it to conduct clinical trials of 225Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.
Lung adenocarcinoma (LUAD) is a subtype of non-small-cell lung cancer (NSCLC) that represents around 40% of all lung tumors. Despite therapeutic advancements, LUAD remains a leading cause of cancer-related death worldwide. Previous research found that ferredoxin-1 (FDX1) dysregulation plays a role in LUAD progression. FDX1 is a crucial regulator of copper homeostasis and cuproptosis, a regulated form of cell death triggered by excessive copper levels.
Beta Pharma Inc. has presented 1,5-naphthyridine derivatives acting as GTPase KRAS (G12D mutant) and/or (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.
Programmed cell death protein 1 (PD-1) is among the immune checkpoint molecules better explored in immunotherapy for cancer. However, it is necessary to obtain novel therapies where preclinical efficacy and safety data could translate into enhanced predictability of human efficacy, pharmacokinetics and side effects.
Georgiamune Inc. has gained FDA clearance for its IND application for GIM-531, a first-in-class oral regulatory T cell (Treg) inhibitor that enables the restoration of a strong immune response against cancer.
The maintenance of mitochondrial homeostasis plays a crucial role in tumor cell survival and growth. Mitochondrial integrity is regulated by proteins in the mitochondrial inner membrane, such as prohibitin (PHB). PHB has been found overexpressed in several cancer types and contributes to tumorigenesis.
Chinese investigators have reported that high levels of triggering receptor expressed on myeloid cells 2 (TREM2) expression, which are immunosuppressive in multiple solid tumors, were protective in glioblastoma multiforme (GBM). The findings were published May 23, 2024, in Cancer Cell.
The American Society of Clinical Oncology (ASCO) begins its 2024 annual meeting at the cavernous and labyrinthine McCormick Place convention center in Chicago Friday, May 31. It’s one of the world’s largest cancer research conferences and can be daunting to follow. More than 400 organizations will participate this year, with about 200 sessions ready to convene. The vast majority of the 5,000 abstracts that cover all aspects of cancer treatment have already been released, and they will be scrutinized by the more than 40,000 attendees from around the world.
China’s Medilink Therapeutics (Suzhou) Co. Ltd. and Germany’s Biontech SE signed another potential $1 billion-plus deal for novel antibody-drug conjugate (ADC) targets, building off the first ADC-based licensing deal from last year.
RSS
